Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
Altamira Therapeutics (Nasdaq: CYTO) announced the expansion of its Bentrio® nasal spray license and distribution agreement with Nuance Pharma. The extended agreement now includes seven additional countries in East and South East Asia, covering a population of over 630 million. Nuance has successfully launched Bentrio in Hong Kong and filed for marketing authorization in Mainland China. The expanded territory includes Singapore, Malaysia, Thailand, Philippines, Indonesia, Vietnam, and Taiwan, in addition to the original markets of China, Hong Kong, Macau, and South Korea.
Thomas Meyer, Altamira Medica's CEO, expressed satisfaction with the collaboration, while Mark G. Lotter, Nuance Pharma's CEO, highlighted Bentrio's unique features and positive market reception. The partnership aims to provide relief to the growing number of allergic rhinitis patients in the region.
Altamira Therapeutics (Nasdaq: CYTO) ha annunciato l'espansione della sua licenza e dell'accordo di distribuzione per il spray nasale Bentrio® con Nuance Pharma. L'accordo esteso ora include sette paesi aggiuntivi in Asia orientale e sud-orientale, coprendo una popolazione di oltre 630 milioni. Nuance ha lanciato con successo Bentrio a Hong Kong e ha presentato domanda di autorizzazione per la commercializzazione in Cina continentale. Il territorio ampliato include Singapore, Malesia, Thailandia, Filippine, Indonesia, Vietnam e Taiwan, oltre ai mercati originali di Cina, Hong Kong, Macao e Corea del Sud.
Thomas Meyer, CEO di Altamira Medica, ha espresso soddisfazione per la collaborazione, mentre Mark G. Lotter, CEO di Nuance Pharma, ha evidenziato le caratteristiche uniche di Bentrio e la positiva accoglienza sul mercato. La partnership mira a fornire sollievo al crescente numero di pazienti affetti da rinite allergica nella regione.
Altamira Therapeutics (Nasdaq: CYTO) anunció la expansión de su licencia y acuerdo de distribución del spray nasal Bentrio® con Nuance Pharma. El acuerdo ampliado ahora incluye siete países adicionales en Asia Oriental y Sudeste Asiático, cubriendo una población de más de 630 millones. Nuance ha lanzado Bentrio con éxito en Hong Kong y ha solicitado la autorización de comercialización en China continental. El territorio ampliado incluye Singapur, Malasia, Tailandia, Filipinas, Indonesia, Vietnam y Taiwán, además de los mercados originales de China, Hong Kong, Macao y Corea del Sur.
Thomas Meyer, CEO de Altamira Medica, expresó satisfacción por la colaboración, mientras que Mark G. Lotter, CEO de Nuance Pharma, destacó las características únicas de Bentrio y la positiva recepción en el mercado. La asociación tiene como objetivo proporcionar alivio al creciente número de pacientes con rinitis alérgica en la región.
알타미라 테라퓨틱스(나스닥: CYTO)는 누안스 파마와의 Bentrio® 비강 스프레이 라이선스 및 배포 계약 확대를 발표했습니다. 확대된 계약은 이제 동아시아와 동남아시아의 추가 7개 국가를 포함하며, 6억 3천만 이상의 인구를 포괄합니다. 누안스는 홍콩에서 Bentrio를 성공적으로 출시하였고, 중국 본토에서의 마케팅 승인을 신청하였습니다. 확대된 지역에는 싱가포르, 말레이시아, 태국, 필리핀, 인도네시아, 베트남 및 대만이 포함되며, 원래의 시장인 중국, 홍콩, 마카오, 대한민국도 포함됩니다.
알타미라 메디카의 CEO인 토마스 마이어는 협력에 대한 만족을 표명했고, 누안스 파마의 CEO인 마크 G. 로터는 Bentrio의 독특한 특성과 긍정적인 시장 반응을 강조했습니다. 이번 파트너십은 이 지역에서 증가하는 알레르기 비염 환자들에게 도움을 주기 위한 것입니다.
Altamira Therapeutics (Nasdaq: CYTO) a annoncé l'extension de son contrat de licence et de distribution du spray nasal Bentrio® avec Nuance Pharma. L'accord élargi comprend désormais sept pays supplémentaires en Asie de l'Est et en Asie du Sud-Est, couvrant une population de plus de 630 millions. Nuance a lancé avec succès Bentrio à Hong Kong et a déposé une demande d'autorisation de mise sur le marché en Chine continentale. Le territoire élargi inclut Singapour, Malaisie, Thaïlande, Philippines, Indonésie, Vietnam et Taïwan, en plus des marchés d'origine de la Chine, Hong Kong, Macao et Corée du Sud.
Thomas Meyer, PDG d'Altamira Medica, a exprimé sa satisfaction quant à la collaboration, tandis que Mark G. Lotter, PDG de Nuance Pharma, a souligné les caractéristiques uniques de Bentrio et la réception positive sur le marché. Ce partenariat vise à soulager le nombre croissant de patients souffrant de rhinite allergique dans la région.
Altamira Therapeutics (Nasdaq: CYTO) gab die Erweiterung ihrer Lizenz- und Vertriebsvereinbarung für das Nasenspray Bentrio® mit Nuance Pharma bekannt. Die erweiterte Vereinbarung umfasst nun sieben zusätzliche Länder in Ost- und Südostasien, die eine Bevölkerung von über 630 Millionen abdecken. Nuance hat Bentrio erfolgreich in Hongkong eingeführt und eine Genehmigung für die Vermarktung in Festlandchina beantragt. Das erweiterte Gebiet umfasst Singapur, Malaysia, Thailand, die Philippinen, Indonesien, Vietnam und Taiwan, zusätzlich zu den ursprünglichen Märkten von China, Hongkong, Macau und Südkorea.
Thomas Meyer, CEO von Altamira Medica, äußerte seine Zufriedenheit mit der Zusammenarbeit, während Mark G. Lotter, CEO von Nuance Pharma, die einzigartigen Merkmale von Bentrio und die positive Marktresonanz hervorhob. Die Partnerschaft zielt darauf ab, den wachsenden Zahl an Patienten mit allergischer Rhinitis in der Region Linderung zu bieten.
- Expansion of Bentrio® nasal spray license and distribution agreement to seven additional countries
- Increased market reach with a combined population of over 630 million people
- Successful launch of Bentrio in Hong Kong
- Marketing authorization request filed for Mainland China
- Positive reception of Bentrio by medical professionals and consumers
- None.
Insights
The expansion of Altamira Therapeutics' license agreement with Nuance Pharma is a positive development for the company. By extending their reach to seven additional countries in East and South East Asia, they're tapping into a market with a population of over 630 million. This significantly increases the potential customer base for Bentrio® nasal spray.
However, investors should note that while this expansion presents growth opportunities, it doesn't guarantee immediate revenue impact. The success will depend on regulatory approvals and market penetration in these new territories. The recent submission for marketing approval in Mainland China is a step in the right direction, but the timeline for approvals and subsequent sales in the new markets remains uncertain.
From a financial perspective, this move could diversify Altamira's revenue streams and potentially reduce market-specific risks. However, the lack of financial details in the announcement makes it difficult to quantify the potential impact on the company's bottom line.
The expansion into South East and East Asian markets is strategically sound. These regions are experiencing rapid economic growth and an increasing prevalence of allergic rhinitis, creating a favorable environment for Bentrio®. The product's unique features, such as immediate onset and long duration of protection, position it well in a market where air quality concerns are prevalent.
Nuance Pharma's existing presence and success in Hong Kong provide a solid foundation for further expansion. Their large sales force and growing partner network could accelerate Bentrio's market penetration. However, each new market will present unique challenges in terms of consumer behavior, healthcare systems and competitive landscape.
Investors should monitor the speed of regulatory approvals and initial sales figures in these new markets as indicators of the expansion's success. The diverse nature of the target countries may require tailored marketing strategies, potentially impacting the cost and timeline of the rollout.
Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) --
- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization for Mainland China
- Extension of Exclusive License and Distribution Agreement to include seven additional countries across East and South East Asia with cumulated population > 630 million
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. has agreed with its partner Nuance Pharma, Shanghai, China (“Nuance”) to extend the territory covered by their exclusive license and distribution agreement for Bentrio® nasal spray by several countries across South East and East Asia. Under the amended agreement, Nuance’s territory will expand from China, Hong Kong, Macau and South Korea to also include Singapore, Malaysia, Thailand, Philippines, Indonesia, Vietnam and Taiwan, with a combined population of greater than 630 million people. Nuance has been marketing Bentrio since late 2022 in Hong Kong and recently submitted the request for marketing approval for Mainland China.
“We are very satisfied with the collaboration with our partner Nuance who has shown great dedication and launched Bentrio successfully in Hong Kong,” commented Thomas Meyer, Altamira Medica’s Chairman and CEO. “Together with Nuance we look forward to making Bentrio available in further countries, first in the existing license territory and subsequently also in the newly added countries to provide relief to the growing number of allergic rhinitis patients in East and South East Asia.“
“We are excited to reinforce and expand our successful collaboration with Altamira on Bentrio,” stated Mark G. Lotter, founder and CEO of Nuance Pharma. “Bentrio offers some unique features such as immediate onset and long duration of protection against airborne particles, strong efficacy and good tolerability thanks to its drug-free and preservative-free formulation. They resonate well with medical professionals and consumers, and we look forward to rolling out the product in additional countries and marketing it through our large sales force and growing network of partners.”
About Bentrio
Bentrio is an “over the counter” drug-free nasal spray for personal protection against airborne allergens and, where approved, against airborne viruses. Upon application into the nose, Bentrio forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of airborne particles with cells; in addition, the composition serves to bind such particles and help with their discharge. The efficacy and safety of Bentrio has been demonstrated in a total of four clinical trials, of which the largest one (“NASAR” study) enrolled 100 patients suffering from seasonal allergic rhinitis. In NASAR, participants self-administered either Bentrio or saline nasal spray for two weeks 3 times per day. The study showed a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrio compared to saline (p = 0.013), as well as a statistically highly significant improvement in health-related quality of life (Rhinoconjunctivitis Quality of Life Questionnaire, p < 0.001) and superior global ratings of efficacy by patients and investigators alike (p < 0.001). In addition, Bentrio showed good safety and tolerability, similar to saline controls, and fewer Bentrio treated patients used relief medication and more of them enjoyed symptom-free days compared to saline treatment. For more information, visit: www.bentrio.com
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a
About Nuance Pharma
Nuance Pharma is a patient-centric and innovation focused biopharmaceutical company, with both clinical and commercial stage assets. Founded by Mark G. Lotter in 2014, with the mission to address critical unmet medical needs in Greater China and Asia Pacific, Nuance has built a late clinical stage innovative portfolio, while maintaining a self-sustainable commercial operation. Focusing on specialty care, Nuance’s portfolio represents a differentiated combination of commercial stage and innovative pipeline assets across respiratory, emergency care, and iron deficiency anemia. For more information, visit: https://www.nuancepharma.com/
Forward-Looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the clinical utility of Altamira’s product candidates, the timing or likelihood of regulatory filings and approvals, Altamira’s intellectual property position and Altamira’s financial position. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira’s Annual Report on Form 20-F for the year ended December 31, 2023, and in Altamira’s other filings with the Securities Exchange Commission (“SEC”), which are available free of charge on the SEC’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Investor Contact:
FAQ
What new countries are included in Altamira's expanded Bentrio distribution agreement with Nuance Pharma?
What is the total population covered by the expanded Bentrio distribution agreement for CYTO?
Has Bentrio nasal spray been launched in any markets under the Altamira-Nuance agreement?
What is the current status of Bentrio's marketing approval in Mainland China for CYTO?
